Verified pilot-to-commercial solutions engineered to transform unstable botanical matrices into high-bioavailability capsule systems.
Bridging traditional botanical pharmacology and cutting-edge oral solid dosage CDMO infrastructure to eliminate batch variance, chemical instability, and unverified bioactivity.
Botanical extracts—specifically crude polysaccharides, glycosides, and polyphenolic extracts—demonstrate aggressive hygroscopic profiles when packed into empty hard gelatin or HPMC capsules. MedGence solves moisture migrations and cross-linking failures via low-temperature microencapsulation and thermodynamic humidity equilibrium matching.
Active natural compounds such as berberine, curcuminoids, and ginsenosides typically suffer from poor aqueous solubility and aggressive CYP-enzyme pre-systemic metabolism. Our formulation architecture deploys self-microemulsifying drug delivery systems (SMEDDS) and micro-pelletized phytosomes inside acid-resistant delayed-release capsules.
Variations across agronomic terroir, climate shifts, and harvest windows cause wide swings in therapeutic potency. We enforce strict chromatographic fingerprinting (HPLC-MS/GC-MS) coupled with raw-material seasonal tracking across Chinese agro-regions, guaranteeing batch-to-batch chemical equivalence for finished commercial capsules.
A structured six-stage translational pipeline spanning early phytochemistry extraction to cGMP contract industrialization.
High-throughput profiling of target botanical species to identify high-affinity secondary metabolites (alkaloids, saponins, flavonoids). Sourcing maps account for plant part and regional yield.
Developing validated quantitative methods under ICH Q2(R1) guidelines, encompassing HPTLC qualitative identity, HPLC content assays, residual solvent monitoring, and pesticide quantitation.
Determination of crystalline structures, moisture sorption isotherms, and excipient compatibility. Implementation of fluid-bed top-spray granulation and high-shear wet granulation for ideal bulk density.
Execution of GLP in vitro receptor-binding assays, acute and sub-chronic animal toxicity models (LD50), Ames genotoxicity testing, and organ-specific metabolic stability profiling.
Double-blind, randomized, placebo-controlled human studies verifying pharmacokinetic profiles (Cmax, Tmax, AUC), safety parameters, and clinical efficacy markers for pharmaceutical and health registrations.
Automated high-speed tamping pin filling into gelatin, plant-derived HPMC, or pullulan capsules under low-humidity cleanrooms. Full secondary blister, bottle, and pouch packaging with nitrogen flush.
Herbal formulations encounter diverse regulatory landscapes across North America, Europe, Australia, and Asia. MedGence engineers dosage forms to conform to specific pharmacopeial and dietary guidelines.
We supply exhaustive documentation packages including botanic taxonomy confirmation, solvent residues according to USP <467>, heavy metal quantitation by ICP-MS (USP <2232>), and support for New Dietary Ingredient (NDI) or GRAS dossiers.
Products target strict microbiological criteria (Ph. Eur. 5.1.8), polycyclic aromatic hydrocarbons (PAH4), and pyrrolizidine alkaloid (PA) screenings, facilitating registrations under EMA traditional herbal medicinal monographs.
Certified clean-label manufacturing featuring halal and kosher compatible vegetable capsules (HPMC/pullulan), heavy-metal assay compliance, and full technical dossier support for listed medicines on the Australian Register of Therapeutic Goods (ARTG).
Pioneering the intersection of artificial intelligence, synthetic biology, and complex plant matrix stabilization.
Deploying deep-learning neural networks to predict multi-target interactions among multi-herb formulations. Our algorithms evaluate active-constituent affinities against human protein datasets, cutting pre-formulation screening timelines by 60%.
Micro-pelletizing phospholipids with polyphenol extracts into controlled-release, multi-particulate systems. This approach shields unstable molecules from gastric juice while enabling extended gut-absorption over 12 to 24 hours.
Transitioning primary processing lines toward green supercritical carbon dioxide and subcritical water extraction systems, completely eliminating halogenated and organic hydrocarbon solvents from botanical yields.
Augmenting chromatographic fingerprinting with molecular genomic sequencing to definitively verify plant genera, species, and sub-types, preventing adulteration by closely related non-active or poisonous flora.
Our formula development, clinical assay datasets, and industrial manufacturing systems support leading pharmaceutical corporations and research hospitals.
China Beijing Tongrentang
China Resources Sanjiu
Sunflower Pharmaceutical Group
Livzon Pharmaceutical Group
Dihon Pharmaceutical Group
Golden Throat Holdings
Yangtzi River Pharma
Humanwell Healthcare Group
Luoxin Pharmaceutical Group
Apeloa Pharmaceutical
Shuguang Hospital (Shanghai TCM)
Second Xiangya Hospital
In-depth responses for formulation scientists, technical directors, and contract procurement executives.
Access our validated research modules, preclinical pipelines, and high-potency capsule contract manufacturing services.
